Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIp Group Regulatory News (IPO)

Share Price Information for Ip Group (IPO)

Share Price is delayed by 15 minutes
Get Live Data
66.20    -1.80 (-2.65%)
Bid:
65.90
Ask:
66.70
Spread: 0.80 (1.214%)
Market Cap: £584.83m
IPO Live PriceLast checked at - London Stock Exchange

Intraday Ip Group Share Chart

Board changes

4 May 2018 07:00

RNS Number : 1008N
IP Group PLC
04 May 2018
 

FOR RELEASE ON

04 May 2018

 

IP Group plc - Board changes

 

IP Group plc (LSE: IPO) ("IP Group" or "the Group" or "the Company"), the developer of intellectual property-based businesses, announces that Mike Humphrey has indicated that for personal reasons he wishes to retire and step down from his position as Non-executive Chairman and a director of the Company as soon as a suitable replacement can be recruited.

 

Mr Humphrey joined the Board of IP Group in October 2011 as a non-executive Director and became Non-executive Chairman in March 2015. He has served as Senior Independent Director, Chairman of the Remuneration Committee and is currently Chairman of the Nomination Committee and a member of the Remuneration Committee.

 

In addition, IP Group announces that Heejae Chae has been appointed as Non-executive Director with immediate effect while Professor Lynn Gladden has indicated that she will be stepping down from her role as Non-executive Director on or prior to 31 December 2018. Professor Gladden has been appointed to the role of Executive Chairman of the Engineering and Physical Sciences Research Council (EPSRC) with effect from 1st of October and, as such, will need to step down from her role at IP Group to avoid any potential conflict of interests.

 

Mr Chae is currently Chief Executive of AIM-listed Scapa Group plc, a global supplier of products for healthcare and industrial markets. Prior to joining Scapa, Mr Chae was Group Chief Executive of Volex Group plc. He was previously the Group General Manager, Radio Frequency Worldwide, for Amphenol Corporation. He spent the early part of his career in finance at The Blackstone Group and Credit Suisse First Boston before moving into industry. Mr Chae has degrees in Economics and Engineering from Columbia University and an MBA from Harvard University. Mr Chae also serves on the Board of Overseers at Boston Children's Hospital and is an Advisory Council Member at Columbia University.

 

Alan Aubrey, Chief Executive of IP Group, said: "Mike has made a significant contribution to the growth of IP Group during his tenure. On behalf of the Board and all of the Company's staff, I would like to thank Mike for his hard work and wise counsel over the years and to wish him well. I would also like to express my thanks to Lynn for her contribution over the last four years and I'm delighted to welcome Heejae Chae to the Board and look forward to working with him."

 

Mike Humphrey, Chairman, said: "Since joining IP Group, the Company has undergone a rapid period of growth which has seen a near ten-fold increase in the value of the portfolio as well as expansion into both the US and Australasia. It has been an honour to work alongside such a talented team and I am confident that the Group will go from strength to strength."

 

A further announcement will be made in due course once Mr Humphrey's replacement has been selected.

 

This announcement is made pursuant to Listing Rule 9.6.11R. There are no other details required to be disclosed under Listing Rule 9.6.13R. There are no further disclosures required under the Disclosure and Transparency Rules.

 

For more information, please contact:

 

IP Group plc

www.ipgroupplc.com

Alan Aubrey, Chief Executive OfficerGreg Smith, Chief Financial OfficerLiz Vaughan-Adams, Communications

+44 (0) 20 7444 0050+44 (0) 20 7444 0062/+44 (0) 7979 853802

Charlotte Street Partners

Andrew Wilson

+44 (0) 7810 636995

Martha Walsh

+44 (0) 7876 245962

 

Notes for editors

 

About IP Group

 

IP Group is a leading intellectual property commercialisation company which focuses on evolving great ideas, mainly from its partner universities, into world-changing businesses. The Group has pioneered a unique approach to developing these ideas and the resulting businesses by providing access to business building expertise, capital (through its 100%-owned FCA-authorised subsidiaries IP Capital and Parkwalk Advisors), networks, recruitment and business support. IP Group has a strong track record of success and its portfolio comprises holdings in early-stage to mature businesses across life sciences and technology. IP Group is listed on the Main Market of the London Stock Exchange under the code IPO.

Group holdings in portfolio companies reflect the undiluted beneficial equity interest excluding debt, unless otherwise explicitly stated.

For more information, please visit our website at www.ipgroupplc.com.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOAVXLFBVEFXBBB
Date   Source Headline
26th Jun 202312:41 pmRNSDirector Declaration
15th Jun 20231:19 pmRNSResult of AGM
15th Jun 20237:00 amRNSAGM Statement
8th Jun 20238:51 amRNSLife Sciences update event
7th Jun 202311:00 amRNSIP Group plc - TR1 form
31st May 20232:34 pmRNSTotal Voting Rights
12th May 20231:26 pmRNSDirector Declaration
10th May 202312:11 pmRNSDirector/PDMR Shareholding
3rd May 202310:56 amRNSDirector Declaration
28th Apr 20233:21 pmRNSTotal Voting Rights
20th Apr 20235:00 pmRNSNotice of AGM, Annual Report
18th Apr 20233:23 pmRNSRSP & DBSP awards; Director/PDMR shareholding
15th Mar 20239:31 amRNSInvestor presentation
13th Mar 20239:00 amRNSDirector/PDMR Shareholding
13th Mar 20237:00 amRNSNo direct deposits or credit facilities with SVB
8th Mar 20237:00 amRNSIP Group plc - Annual Results
2nd Mar 20233:25 pmRNSTR-1
21st Feb 20237:00 amRNSAMSL Aero's all-electric aircraft maiden flight
10th Feb 20239:55 amRNSNotice of Results
31st Jan 202310:00 amRNSTotal Voting Rights
30th Jan 20237:00 amRNSStatement re press speculation
24th Jan 20231:18 pmRNSForm 8.3 - Mirriad Advertising plc
18th Jan 20237:00 amRNSDirectorate Change
11th Jan 20237:00 amRNSPortfolio company Oxbotica raises $140m Series C
3rd Jan 202311:48 amRNSTotal Voting Rights
12th Dec 20224:58 pmRNSAGM post-meeting shareholder engagement update
7th Dec 20224:39 pmRNSHolding(s) in Company
5th Dec 20227:00 amRNSIstesso announces FDA Fast Track for MBS2320
2nd Dec 202211:38 amRNSPortfolio company funding leads to £36m gain
30th Nov 202210:41 amRNSTotal Voting Rights
21st Nov 20222:13 pmRNSLife sciences presentation postponed
2nd Nov 20223:51 pmRNSInvestor presentation on life sciences
1st Nov 20228:59 amRNSNotification of major holdings
31st Oct 20224:35 pmRNSDirector/PDMR Shareholding
27th Oct 20224:55 pmRNSPDMR Dealing – SAYE Exercise
24th Oct 20226:02 pmRNSHolding(s) in Company
14th Oct 20229:42 amRNSHolding(s) in Company
30th Sep 202210:39 amRNSTotal Voting Rights
21st Sep 20225:29 pmRNSHolding(s) in Company
20th Sep 20226:10 pmRNSDirector/PDMR Shareholding
15th Sep 20224:41 pmRNSInvestor presentation
14th Sep 20224:33 pmRNSFurther re Scrip Dividend
13th Sep 20226:00 pmRNSFurther re Interim Scrip Dividend
13th Sep 20227:01 amEQSIP Group Trust (IPO): Initiation — International investor in impactful innovation
7th Sep 20224:33 pmRNSDirector/PDMR Shareholding, SAYE scheme
31st Aug 20228:51 amRNSIstesso starts Phase 2b trial of MBS2320
30th Aug 202212:59 pmRNSCash acquisition of portfolio company Diurnal
18th Aug 20229:25 amRNSScrip Dividend Reference Price
11th Aug 202210:50 amRNSHolding(s) in Company
3rd Aug 20227:00 amRNSHalf-yearly results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.